树突状细胞-细胞因子诱导杀伤细胞免疫治疗预计生存期低于3月的晚期恶性肿瘤患者

目的 探讨预计生存期小于3月的晚期肿瘤患者是否会从DC-CIK治疗中获益。方法 对13例预计生存期小于3月、ECOG评分大于3的患者进行DC-CIK治疗，同时检测治疗前后T淋巴细胞亚群的变化，对比治疗前后ECOG评分的变化，统计OS，观察不良反应。结果 末次DC-CIK治疗后两个月与治疗前对比，CD3+T细胞的增加和CD8+CD28-T细胞的减少差异有统计学意义。通过DC-CIK治疗11位患者ECOG评分得到改善，11位患者OS大于预计的3月，而且有7位患者至随访末仍然生存（均已大于6月），无明显不良反应发生。结论 预计生存期小于3月的晚期肿瘤患者行DC-CIK治疗，是安全有效的。

Clinical Analysis of Patients Suffering from Advanced Malignancy with Survival Time Less Than 3 Months by DC-CIK Cells

Objective To investigate whether the patients suffering from advanced malignancy withexpected survival time less than 3 months will benefit from DC-CIK immunotherapeutic treatments.Methods Thirteen eligible patients with ECOG performance greater than 3 and expected survival timeless than 3 months, were treated with DC-CIK immunotherapy. The level of peripheral blood T lymphocytessubsets were measured before and after DC-CIK infusions. The primary observations were the changesin ECOG performance, overall survival and adverse reactions. Results The levels of CD3+T cells wereincreased and CD8+CD28- T cells were reduced in two months after the last DC-CIK treatment, withstatistical signifi cance. Through the DC-DIK treatment, the ECOG performance improved in 11 patients andoverall survival of the 11 patients was prolonged for 3 months. And there were 7 patients still alive at the endof follow-up (already more than 6 months). No severe adverse reactions occurred. Conclusion DC-CIKimmunotherapy is effective and safe for advanced cancer patients with expected survival less than 3 months.